The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Arcus Biosciences Inc shares valued at $681,342 were sold by Jaen Juan C. on Jan 05 ’26. At $21.41 per share, Jaen Juan C. sold 31,823 shares. The insider’s holdings dropped to 922,240 shares worth approximately $19.69 million following the completion of this transaction.
Also, Juan Jaen purchased 31,823 shares, netting a total of over 692,787 in proceeds.
Before that, Goeltz II Robert C. had sold 6,552 shares from its account. In a trade valued at $153,186, the Chief Financial Officer traded Arcus Biosciences Inc shares for $23.38 each. Upon closing the transaction, the insider’s holdings decreased to 6,552 shares, worth approximately $1.45 million.
As published in a research note from Morgan Stanley on January 08, 2026, Arcus Biosciences Inc [RCUS] has been rated down from an Overweight to an Equal-weight and the price target has been revised to $20. Analysts at H.C. Wainwright upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in late February. As of October 21, 2024, H.C. Wainwright has initiated its “Neutral” rating for RCUS. Earlier on October 08, 2024, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for RCUS stock.
Analyzing RCUS Stock Performance
On last trading session, Arcus Biosciences Inc [NYSE: RCUS] plunged -7.97% to $21.35. The stock’s lowest price that day was $20.86, but it reached a high of $22.5 in the same session. During the last five days, there has been a drop of approximately -10.41%. Over the course of the year, Arcus Biosciences Inc shares have jumped approximately 43.58%. Shares of the company reached a 52-week high of $23.99 on 01/02/26 and a 52-week low of $20.59 on 01/05/26.
Support And Resistance Levels for Arcus Biosciences Inc (RCUS)
According to the 24-hour chart, there is a support level at 20.64, which, if violated, would cause prices to drop to 19.93. In the upper region, resistance lies at 22.28. The next price resistance is at 23.21. RSI (Relative Strength Index) is 42.73 on the 14-day chart, showing neutral technical sentiment.
Is Arcus Biosciences Inc subject to short interest?
Stocks of Arcus Biosciences Inc saw a sharp steep in short interest on 2025-12-15 dropping by -2.06 million shares to 7.83 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 9.89 million shares. A decline of -26.28% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.47 of the overall float, the days-to-cover ratio (short ratio) decline to 3.47.
Which companies own the most shares of Arcus Biosciences Inc (RCUS)?
In terms of Arcus Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 30 in the next 12 months, up nearly 29.31% from the previous closing price of $23.2. Analysts anticipate Arcus Biosciences Inc stock to reach 35 by 2026, with the lowest price target being 16. In spite of this, 3 analysts ranked Arcus Biosciences Inc stock as Buy at the end of 2026. On November 18, 2022, BofA Securities assigned a price target of “a Neutral” to the stock and initiated coverage with a $33.
